Franssen, Stijn
Holster, Jessica J.
Jolissaint, Joshua S.
Nooijen, Lynn E.
Cercek, Andrea
D’Angelica, Michael I.
Homs, Marjolein Y. V.
Wei, Alice C.
Balachandran, Vinod P.
Drebin, Jeffrey A.
Harding, James J.
Kemeny, Nancy E.
Kingham, T. Peter
Klümpen, Heinz-Josef
Mostert, Bianca
Swijnenburg, Rutger-Jan
Soares, Kevin C.
Jarnagin, William R.
Groot Koerkamp, Bas http://orcid.org/0000-0003-1917-6973
Article History
Received: 7 June 2023
Accepted: 18 September 2023
First Online: 9 October 2023
Disclosure
: Dr. James Harding. Research Support to Institution: Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Loxo @ Lilly, Novartis, Polaris, Pfizer, Zymeworks, and Yiviva. Consulting/Advisory: Adaptimmune, Astrazenica, Bristol Myers Squibb, Exelexis, Elevar, Eisai, Genoscience (uncompensated), Hepion, Imvax, Merck (DSMB) Medivir, QED, Tyra, and Zymeworks (uncompensated).